Bioregnum channel feed – Endpoints News

SIGN UP

Bioregnum channel feed

The Endpoints 100 survey: Has biotech hit rock bottom?

Yesterday

Flagship Pioneering takes another big step across the globe, planting its biotech flag in Asia

Last month

Longtime cancer R&D chief Peter Lebowitz is taking his final bows at J&J oncology. Now what?

Last month

I'll be in London next week with the Endpoints crew and a great lineup of biotech experts and insiders. Join us

2 months ago

Q3 snapshot: The IPO market shows fresh signs of improvement, but the biotech crunch continues to bite

2 months ago

Exclusive: AstraZeneca signs off on a ‘carbon negative’ new biotech building for one of its latest buyouts

2 months ago

Did I ever tell you the one about the drunken biotech awards program I hosted at a Chicago bar?

2 months ago

Astellas builds its R&D footprint in Cambridge/Boston with an add-on for labs, offices

4 months ago

As SQZ faced a final reckoning, a fateful board decision steered the company to a quick and brutal endgame

4 months ago

The veteran crew at Medicxi is back with a new $400M fund and an upbeat assessment of what's coming

4 months ago

Faheem Hasnain gets a $212M stake together for his big PhIII gamble — here’s why investors are letting it ride

4 months ago

A small Swiss biotech tackles a huge global health issue with a handoff from GSK. But can it make any money from it?

4 months ago

Pfizer, Flagship ally on a $100M cash launch of a drug discovery expedition

4 months ago

Bill Haney adds a matching $100,000 contribution to Kristen Hege's adventurous fundraiser backing women scientists

4 months ago

After ejecting out of Bristol Myers R&D, Rupert Vessey lands at the top science post at a buzzy Flagship

4 months ago

Tessa enjoyed big backers, great science and world-class ambition. So what did we learn from its collapse?

5 months ago

The H1 picture: Biotech’s vital signs show some life — with one big exception

5 months ago

The Endpoints 11 is back: Nominate your favorite biotech for our annual report on the most promising startups in the world

5 months ago

AstraZeneca enlists an upstart China biotech partner in the wake of an R&D setback

5 months ago

Bristol Myers offers a $100,000 vote of support for Kristen Hege's adventurous fundraising campaign

5 months ago

Who's confidently investing in biotech startups during these tense days? We've got some answers

6 months ago

Amit Munshi has more than $300M and a startup CSO out to pioneer next-gen RNA therapeutics. Once again, he’s thinking big

6 months ago

Ex-FDA neuro chief Billy Dunn is taking a spin through the revolving door with biopharma — and that's a problem

6 months ago

The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there's a lot for biotech execs to deal with

7 months ago

12 3 4 Next page Last page